This disclosure relates to pharmaceutical packaging units comprising different radiotracers and methods of using the same.

A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [.sup.123I]-2β-carbomethoxy-3β-(4-flurophenyl)-N-(3-iodo-E-allyl) nortropane.

Disclosed is a method of increasing the rate of delivery of an active compound or agent to the brain across the blood brain barrier of a subject. In one aspect, the disclosure provides an accelerated method of providing an active compound to a targeted region of the brain of a subject, served by the cerebral medial artery, the method comprising: administering a sub-anesthetic dose of xenon as an inhalant to the subject; and administering an efficacious amount of the active compound to the bloodstream of the subject, the active compound reaching the targeted region of the brain in less time relative to a time it takes to reach the targeted region without xenon administration.

This disclosure relates to methods of determining if a subject not manifesting any clinical symptoms of a dopaminergic disorder is afflicted with the dopaminergic disorder using radiolabeled DatT020 or a derivative thereof.

Provided are methods of evaluating an ability of a therapeutic composition to modulate a dopaminergic activity in an organ of a mammalian subject having a dopaminergic disorder. Also provided are methods of assessing and monitoring the progression of a dopaminergic disorder in tan organ of a mammalian subject, and of optimizing the treatment of such a disorder.

The present application provides a means for differential diagnosis of Parkinson's disease and the clinically similar Parkinsonian disorders multiple system atrophy with predominantly Parkinsonian features (MSA-P) and progressive supranuclear palsy (PSP).

The invention provides methods and material for diagnosis and treatment of ccRCC. Thus, the invention relates to a method for diagnosis or treatment of clear cell renal cell carcinoma (ccRCC) in an individual in an individual in need thereof, wherein the method comprises use of an SLC6A3 ligand linked to a radioactive label, a cytotoxic moiety or an immunomodulatory moiety.

The present invention provides an automated method for the preparation of .sup.123I-labelled radiopharmaceutical compositions, together with disposable cassettes for use in the method. The use of an automated synthesizer apparatus in the preparation of .sup.123I-labelled radiopharmaceuticals is also described. Also described is the use of cassettes of the present invention in the preparation of .sup.123I-labelled radiopharmaceuticals.

Various compositions and methods for Quasi-Amadori products and derivatives thereof are contemplated in which a halogenated carbohydrate is reacted with a primary amino group of an affinity ligand. In especially preferred aspects, the Quasi-Amadori product is formed from 2-fluorodeoxyglucose and an affinity moiety that preferentially or selectively binds to a neural cell or neural structure. Where contemplated compounds include .sup.18F, PET imaging using compounds presented herein is especially preferred.